Long-term results of a phase 2 study (NCT02211131) revealed consistent efficacy at 5 years with talimogene laherparepvec in stage IIIB to IVM1a melanoma.
2022
Naporafenib Combinations Prove Effective in NRAS-Mutant Unresectable/Metastatic Melanoma
The investigational type II RAF inhibitor naporafenib exhibited favorable efficacy with a tolerable safety profile in combination with rineterkib, trametinib (Mekinist), or ribociclib (Kisqali) in patients with previously treated, unresectable or metastatic melanoma, according to results from a phase 2 trial (NCT04417621) presented at the ESMO Congress 2022.
Kelsie’s melanoma diagnosis leaves doctors unsure about best medical treatment
Kelsie Dummètt is only in her 20s but she’s already made a will.
Addition of Neoadjuvant Pembrolizumab Improves EFS in Resectable Melanoma
Compared with adjuvant pembrolizumab (Keytruda) alone, the addition of neoadjuvant pembrolizumab significantly improved event-free survival (EFS) outcomes for patients with stage III-IV melanoma with a hazard ratio of 0.58 (95% CI, 0.39-0.87; P = .004), according to data from the phase 2 SWOG S1801 trial (NCT03698019).